OCT-Based Retina Assessment Reflects Visual Impairment in Multiple Sclerosis
AULCSF outperformed standard HCVA and LCVA, closely reflecting retinal atrophy. mGCIPL loss showed stronger associations with vision tests and detected neurodegeneration without the cutoff effect seen in pRNFL, making it the best marker for neuronal atrophy.
Authors
- Natacha Stolowy (ORCID: https://orcid.org/0000-0003-3662-3800)
- Thierry David
- Michael Dörr (ORCID: https://orcid.org/0000-0002-7879-7908)
- Christoph Heesen (ORCID: https://orcid.org/0000-0001-8131-9467)
- Christina Mayer (ORCID: https://orcid.org/0000-0002-4148-2822)
- Friedemann Paul (ORCID: https://orcid.org/0000-0002-6378-0070)
- Hanna Zimmermann (ORCID: https://orcid.org/0000-0002-0276-8051)
- Ting‐Yi Lin (ORCID: https://orcid.org/0000-0001-9605-8095)
- Frederike Cosima Oertel (ORCID: https://orcid.org/0000-0003-4906-5983)
- Lilija Gutmann
- Jan‐Patrick Stellmann
- Margareta Lüpke
Institutions
- Centre National de la Recherche Scientifique (FR)
- Johns Hopkins University (US)
- Universität Hamburg (DE)
- Max Delbrück Center (DE)
- Aix-Marseille Université (FR)
- Humboldt-Universität zu Berlin (DE)
- Einstein Center Digital Future (DE)
- Hôpital de la Conception (FR)
- University Medical Center Hamburg-Eppendorf (DE)
- Centre de Résonance Magnétique Biologique et Médicale (FR)
- Hôpital de la Timone (FR)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Investigative Ophthalmology & Visual Science
- Published
- 2025-02-13
- DOI
- https://doi.org/10.1167/iovs.66.2.39
- Citations
- 1
- Primary Topic
- Retinal and Optic Conditions
- Type
- article
- Field-Weighted Citation Impact
- 1.71
Funders
- Sanofi
- Biogen
- Alexion Pharmaceuticals
- Celgene
- European Committee for Treatment and Research in Multiple Sclerosis
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung
- Neuraxpharm
- Sanofi Genzyme